With the introduction of tyrosine kinase inhibitors (TKIs) to target BCR::ABL1, the overall survival (OS) of CML patients has markedly improved as demonstrated by multiple studies and real-world data [4,5]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.